COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #47 of 231
5/28 Late treatment study
Huang et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113 (Peer Reviewed)
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Source   PDF   Share   Tweet
197 CQ patients, 176 control. Mean time to undetectable viral RNA and duration of fever significantly reduced. No serious adverse events.

Huang et al., 5/28/2020, prospective, China, Asia, peer-reviewed, 36 authors.
time to viral-, 67.0% lower, relative time 0.33, p < 0.001, treatment 197, control 176.
time to viral-, 59.1% lower, relative time 0.41, p < 0.001, treatment 32, control 37, early treatment.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.